bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1712762
Sentiment: neutral
Topics: 8-k, filing, financials
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on Sept 9th, likely with financial updates. Check for details.
AI Summary
On September 9, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that bioAffinity Technologies, Inc. has made a significant disclosure to the SEC, which could contain important updates for investors regarding financial performance or other material events.
Risk Assessment
Risk Level: medium — 8-K filings can contain material information, but the provided excerpt lacks specific details to assess the immediate impact or risk.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- September 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (identifier) — Commission File Number
- 46-5211056 (identifier) — I.R.S. Employer Identification Number
- 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 (address) — Principal executive offices
FAQ
What specific "Other Events" are being reported by bioAffinity Technologies, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported, only that this item is included in the filing.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The excerpt states that "Financial Statements and Exhibits" are part of the filing, but does not list their specific contents.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 9, 2025.
What is the principal executive office address for bioAffinity Technologies, Inc.?
The principal executive office address is 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number for bioAffinity Technologies, Inc. is 001-41463.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-09 16:15:25
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 26KB
- 0001641172-25-026971.txt ( ) — 303KB
- biaf-20250909.xsd (EX-101.SCH) — 4KB
- biaf-20250909_def.xml (EX-101.DEF) — 26KB
- biaf-20250909_lab.xml (EX-101.LAB) — 36KB
- biaf-20250909_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 9, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-